RESPIRERX PHARMACEUTICALS INC.

Filed Date	Form Type	Description	View
11/14/2025	Form REVOKED	Commission order revoking Exchange Act registration [Section 12(j)]
02/10/2025	Form 8-K	Current Report
09/06/2024	Form 8-K	Current Report
08/02/2024	Form 8-K	Current Report
07/08/2024	Form 8-K	Current Report
05/29/2024	Form 8-K	Current Report
04/16/2024	Form 8-K	Current Report
04/01/2024	Form NT 10-K	Notification of inability to timely file Form 10-K
02/02/2024	Form 8-K	Current Report
01/22/2024	Form 8-K	Current Report
12/11/2023	Form 8-K	Current Report
11/17/2023	Form 10-Q	Quarterly Report
11/14/2023	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
10/12/2023	Form 8-K	Current Report
10/02/2023	Form 8-K	Current Report
08/21/2023	Form 10-Q	Quarterly Report
08/14/2023	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
08/09/2023	Form 8-K	Current Report
06/13/2023	Form 8-K	Current Report
05/24/2023	Form 8-K	Current Report
05/22/2023	Form 10-Q	Quarterly Report
05/15/2023	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
05/05/2023	Form 8-K	Current Report
04/17/2023	Form 10-K	Annual Report
04/13/2023	Form 8-K	Current Report
04/06/2023	Form 8-K	Current Report
03/31/2023	Form NT 10-K	Notification of inability to timely file Form 10-K
03/28/2023	Form 8-K	Current Report
03/01/2023	Form 8-K	Current Report
02/01/2023	Form 8-K	Current Report
01/23/2023	Form 8-K	Current Report
01/12/2023	Form 8-K	Current Report
11/17/2022	Form 10-Q	Quarterly Report
11/17/2022	Form 8-K	Current Report
11/14/2022	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
11/10/2022	Form 8-K	Current Report
11/07/2022	Form 8-K	Current Report
09/13/2022	Form 8-K	Current Report
08/22/2022	Form 10-Q	Quarterly Report
08/15/2022	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
08/03/2022	Form 8-K	Current Report
06/16/2022	Form 8-K	Current Report
05/23/2022	Form 10-Q	Quarterly Report
05/16/2022	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
05/16/2022	Form 8-K	Current Report
04/15/2022	Form 10-K	Annual Report
04/04/2022	Form 8-K	Current Report
03/31/2022	Form NT 10-K	Notification of inability to timely file Form 10-K
03/28/2022	Form 8-K	Current Report
03/23/2022	Form 8-K	Current Report
03/08/2022	Form 253G2	Reflects information covered in both 253G1 and 253G2
03/07/2022	Form 8-K	Current Report
02/17/2022	Form 253G2	Reflects information covered in both 253G1 and 253G2
02/11/2022	Form 8-K	Current Report
01/10/2022	Form 253G2	Reflects information covered in both 253G1 and 253G2
01/10/2022	Form 8-K	Current Report
01/03/2022	Form 253G2	Reflects information covered in both 253G1 and 253G2
12/29/2021	Form 8-K	Current Report
12/14/2021	Form 253G2	Reflects information covered in both 253G1 and 253G2
12/14/2021	Form 8-K	Current Report
12/14/2021	Form 253G2	Reflects information covered in both 253G1 and 253G2
12/14/2021	Form 8-K	Current Report
12/14/2021	Form 253G3	Reflects information covered in both 253G1 and 253G2
12/13/2021	Form QUALIF	Notice of Qualification
12/01/2021	Form 1-A/A	[Amend] Offering Statement [Regulation A]
11/23/2021	Form 8-K	Current Report
11/22/2021	Form 8-K	Current Report
11/15/2021	Form 10-Q	Quarterly Report
11/04/2021	Form 8-K	Current Report
10/12/2021	Form 1-A/A	[Amend] Offering Statement [Regulation A]
10/12/2021	Form 8-K	Current Report
09/28/2021	Form 8-K	Current Report
09/20/2021	Form 8-K	Current Report
09/03/2021	Form 8-K	Current Report
08/16/2021	Form 10-Q	Quarterly Report
08/09/2021	Form 1-A	Offering Statement [Regulation A]
07/30/2021	Form S-8	Securities to be offered to employees in employee benefit plans
07/30/2021	Form 8-K	Current Report
07/06/2021	Form 8-K	Current Report
05/24/2021	Form 10-Q	Quarterly Report
05/17/2021	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
05/14/2021	Form 8-K	Current Report
05/06/2021	Form 8-K	Current Report
05/03/2021	Form 8-K	Current Report
04/15/2021	Form 10-K	Annual Report
04/05/2021	Form 8-K	Current Report
03/31/2021	Form NT 10-K	Notification of inability to timely file Form 10-K
03/22/2021	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
02/19/2021	Form 424B3	Prospectus filed pursuant to Rule 424(b)(3)
02/19/2021	Form 8-K	Current Report
02/08/2021	Form 424B3	Prospectus filed pursuant to Rule 424(b)(3)
01/20/2021	Form 8-K	Current Report
01/05/2021	Form 8-K	Current Report
12/14/2020	Form 8-K	Current Report
12/01/2020	Form 424B3	Prospectus filed pursuant to Rule 424(b)(3)
12/01/2020	Form 8-K	Current Report
11/25/2020	Form 8-K	Current Report
11/24/2020	Form 424B3	Prospectus filed pursuant to Rule 424(b)(3)
11/23/2020	Form 10-Q	Quarterly Report
11/16/2020	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
11/12/2020	Form 8-K	Current Report
11/02/2020	Form UPLOAD	[Cover]SEC-generated letter
10/30/2020	Form DEF 14A	Definitive Proxy Statements
10/30/2020	Form PRER 14A	Preliminary Proxy Soliciting materials
10/28/2020	Form EFFECT	Notice of Effectiveness
10/28/2020	Form CORRESP	Correspondence
10/28/2020	Form 424B3	Prospectus filed pursuant to Rule 424(b)(3)
10/28/2020	Form UPLOAD	[Cover]SEC-generated letter
10/26/2020	Form CORRESP	Correspondence
10/26/2020	Form S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
10/20/2020	Form PRE 14A	Other preliminary proxy statements
10/16/2020	Form UPLOAD	[Cover]SEC-generated letter
10/14/2020	Form S-1	General form for registration of securities under the Securities Act of 1933
10/06/2020	Form 4	Statement of changes in beneficial ownership of securities
10/06/2020	Form 3	Initial Statement of Beneficial Ownership of Securities
10/05/2020	Form 8-K	Current Report
10/02/2020	Form 4	Statement of changes in beneficial ownership of securities
10/02/2020	Form 4	Statement of changes in beneficial ownership of securities
10/02/2020	Form 4	Statement of changes in beneficial ownership of securities
10/02/2020	Form 4	Statement of changes in beneficial ownership of securities
09/25/2020	Form 8-K	Current Report
09/15/2020	Form S-8	Securities to be offered to employees in employee benefit plans
08/19/2020	Form 10-Q	Quarterly report
08/14/2020	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
08/12/2020	Form D	Statement of acquisition of beneficial ownership by individuals
08/12/2020	Form D	Statement of acquisition of beneficial ownership by individuals
08/05/2020	Form 8-K	Current Report
08/04/2020	Form 4	Statement of changes in beneficial ownership of securities
08/04/2020	Form 4	Statement of changes in beneficial ownership of securities
08/04/2020	Form 4	Statement of changes in beneficial ownership of securities
08/04/2020	Form 3	Initial Statement of Beneficial Ownership of Securities
08/03/2020	Form 8-K	Current Report
07/15/2020	Form 4	Statement of changes in beneficial ownership of securities
07/13/2020	Form 8-K	Current Report
07/07/2020	Form 8-K	Current Report
06/26/2020	Form 8-K	Current Report
06/11/2020	Form 8-K	Current Report
05/20/2020	Form 10-Q	Quarterly report
05/15/2020	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
05-06-2020	Form 8-K	Current Report
04-21-2020	Form 8-K	Current Report
04-14-2020	Form 10-K	Annual Report
04-10-2020	Form DEF 14C	Definitive Information Statements
03-30-2020	Form NT 10-K	Notification of inability to timely file Form 10-K
03-26-2020	Form 8-K	Current Report
03-24-2020	Form 4	Statement of changes in beneficial ownership of securities
03-24-2020	Form 4	Statement of changes in beneficial ownership of securities
03-24-2020	Form PRE 14C	Other preliminary Information Statements
03-19-2020	Form 8-K	Current Report
03-09-2020	Form 8-K	Current Report
03-05-2020	Form 8-K	Current Report
03-04-2020	Form 8-K	Current Report
02-12-2020	Form 8-K	Current Report
02-03-2020	Form 8-K	Current Report
12-30-2019	Form 8-K	Current Report
12-18-2019	Form 8-K	Current Report
11-19-2019	Form 10-Q	Quarterly Report
11-14-2019	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
11-05-2019	Form 8-K	Current Report
10-28-2019	Form 8-K	Current Report
09-09-2019	Form 8-K	Current Report
08-27-2019	Form 8-K	Current Report
08-14-2019	Form 10-Q	Quarterly Report
05-23-2019	Form 8-K	Current Report
05-20-2019	Form 10-Q	Quarterly Report
05-15-2019	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
04-30-2019	Form 8-K	Current Report
04-16-2019	Form 10-K	Annual Report
04-01-2019	Form NT 10-K	Notification of inability to timely file Form 10-K
03-05-2019	Form 8-K	Current Report
01-04-2019	Form 8-K	Current Report
12-20-2018	Form CT ORDER	Confidential treatment order
12-17-2018	Form 8-K	Current Report
12-10-2018	Form 8-K	Current Report
11-16-2018	Form 10-Q	Quarterly Report
11-14-2018	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
10-15-2018	Form 10-Q	Quarterly Report
09-28-2018	Form 8-K	Current Report
09-24-2018	Form D	Notice of Exempt Offering of Securities
09-14-2018	Form 4	Statement of changes in beneficial ownership of securities
09-13-2018	Form 8-K	Current Report
09-10-2018	Form 8-K	Current Report
08-15-2018	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
06-29-2018	Form 8-K/A	Amendment to Form 8-K
06-19-2018	Form 8-K	Current Report
06-19-2018	Form 8-K	Current Report
06-06-2018	Form 8-K	Current Report
05-21-2018	Form 10-Q	Quarterly Report
05-15-2018	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
04-17-2018	Form 10-K	Annual Report
04-11-2018	Form 8-K	Current Report
04-02-2018	Form NT 10-K	Notification of inability to timely file Form 10-K
01-08-2018	Form 8-K	Current Report
01-05-2018	Form 8-K	Current Report
12-14-2017	Form 8-K	Current Report
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
12-12-2017	Form 4	Statement of changes in beneficial ownership of securities
11-20-2017	Form 10-Q	Quarterly Report
11-14-2017	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
10-03-2017	Form 8-K	Current Report
09-13-2017	Form D	Notice of Exempt Offering of Securities
09-08-2017	Form 8-K	Current Report
08-30-2017	Form 8-K	Current Report
08-14-2017	Form 10-Q	Quarterly Report
07-28-2017	Form 4	Statement of changes in beneficial ownership of securities
07-18-2017	Form 8-KA	Amendment to Form 8-K
07-11-2017	Form 8-K	Current Report
07-07-2017	Form 8-K	Current Report
07-06-2017	Form 4	Statement of changes in beneficial ownership of securities
07-05-2017	Form 4	Statement of changes in beneficial ownership of securities
07-05-2017	Form 4	Statement of changes in beneficial ownership of securities
07-05-2017	Form 4	Statement of changes in beneficial ownership of securities
07-05-2017	Form 4	Statement of changes in beneficial ownership of securities
07-05-2017	Form 4	Statement of changes in beneficial ownership of securities
06-16-2017	Form 8-K	Current Report
06-06-2017	Form 8-K	Current Report
05-19-2017	Form 10-Q	Quarterly Report
05-16-2017	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
04-03-2017	Form 8-K	Current Report
03-31-2017	Form 10-K	Annual Report
03-23-2017	Form D	Notice of Exempt Offering of Securities
03-16-2017	Form 8-K	Current Report
02-23-2017	Form 8-K	Current Report
02-10-2017	Form 8-K	Current Report
01-23-2017	Form 8-K	Current Report
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-20-2017	Form 4	Statement of Changes in Beneficial Ownership of Securities
01-13-2017	Form D	Notice of Exempt Offering of Securities
01-06-2017	Form 8-K	Current Report
01-05-2017	Form 8-K	Current Report
12-23-2016	Form 8-K	Current Report
12-15-2016	Form 8-K	Current Report
11-14-2016	Form 10-Q	Quarterly Report
11-01-2016	Form 8-K	Current Report
10-31-2016	Form 8-K	Current Report
10-17-2016	Form 8-K	Current Report
10-07-2016	Form 8-K	Current Report
10-04-2016	Form 8-K	Current Report
09-28-2016	Form 8-K	Current Report
09-28-2016	Form 8-K	Current Report
09-12-2016	Form 8-K	Current Report
09-01-2016	Form 8-K	Current Report
08-22-2016	Form 8-K	Current Report
08-12-2016	Form 10-QA	Amendment to Form 10-Q
08-12-2016	Form 10-Q	Quarterly Report
07-19-2016	Form 4	Statement of changes in beneficial ownership of securities
07-13-2016	Form 8-K	Current report
07-08-2016	DEF 14A	Definitive Proxy Statements
06-20-2016	Form 4	Statement of changes in beneficial ownership of securities
06-20-2016	Form 4	Statement of changes in beneficial ownership of securities
06-08-2016	Form 8-k	Current report
06-07-2016	PRE 14A	Other preliminary proxy statements
05-18-2016	Form S-8	Initial Registration Statement for Securities to be offered to Employees Pursuant to Employee Benefit Plans.
05-13-2016	Form 10-Q	Quarterly Report
05-10-2016	Form 8-K	Current Report
04-12-2016	FORM 8-KA	Amendment to FORM 8-K
04-11-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-11-2016	Form 8-K	Current Report
04-06-2016	Form 8-K	Current Report
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
04-04-2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
03-29-2016	Form 10-K	Annual Report
03-11-2016	Form 8-K	Current Report
02-29-2016	Form 8-K	Current Report
02-04-2016	8-K	Current Report
02-03-2016	8-K	Current Report
01-20-2016	Form D	Notice of Exempt Offering of Securities
01-19-2016	Form 8-K	Current Report
01-19-2016	Form 8-K	Current Report
01-11-2016	Form 8-K	Current Report
01-11-2016	Form 8-K	Current Report
12-17-2015	Form 8-K	Current Report
11-13-2015	Form S-8	Securities to be offered to employees in employee benefit plans
11-12-2015	Form 10-Q	Quarterly Report
11-05-2015	Form8-K	Current Report
11-02-2015	Form8-K/A	[Amend] Current Report
10-20-2015	Form 8-K	Current Report
10-02-2015	Form 8-K	Current Report
09-11-2015	Form D	Notice of Exempt Offering of Securities
09-08-2015	Form8-K	Current Report
08-31-2015	Form 4	Statement of changes in beneficial ownership of securities
08-31-2015	Form 8-K	Current Report
08-20-2015	Form 4/A	Amendment to Form 4
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
08-20-2015	Form 3	Initial Statement of Beneficial Ownership of Securities
08-19-2015	Form 8-K	Current Report
08-13-2015	Form 10Q	Quarterly Report
08/07/2015	Form 10-Q/A	Amendment to Form 10-Q
07/31/2015	Form 8-K	Current Report.
07/10/2015	Form 8-K/A	Amendment to Form 8-K
07/09/2015	Form 8-K	Current Report
07/08/2015	Form 8-K	Current Report
07/06/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/06/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/06/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/02/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/02/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/02/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
06/19/2015	Form 8-K	Current Report
06/02/2015	Form 144	Proposed Sale of Securities
05/18/2015	Form 8-K/A	Amendment to Form 8-K
05/14/2015	Form 10-Q	Quarterly Report
05/13/2015	Form DEF 14C	Definitive Information Statements.
05/13/2015	Form UPLOAD	[Cover]SEC-generated letter
05/11/2015	Form CORRESP	Correspondence
05/11/2015	Form PRER 14C	Preliminary Revised Information Statements
05/04/2015	Form 8-K	Current Report
05/01/2015	Form UPLOAD	[Cover]SEC-generated letter
05/01/2015	Form 8-K	Current Report
04/23/2015	Form Pre 14C	Preliminary Information Statement
04/21/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
04/21/2015	Form 3	Initial Statement of Beneficial Ownership of Securities
03/30/2015	Form 10-K	Annual Report
03/09/2015	Form 10-Q	Quarterly Report
02/24/2015	Form 10-Q	Quarterly Report
02/10/2015	Form 10-Q	Quarterly Report
02/06/2015	Form 8-K	Current Report
01/13/2015	Form 8-K	Current Report
01/07/2015	Form 8-K	Current Report
01/06/2015	Form 10-K	Annual Report
12/15/2014	Form 10-Q	Quarterly Report
12/15/2014	Form 10-Q	Quarterly Report
11/24/2014	Form 10-Q	Quarterly Report
11/17/2014	Form D	Notice of Exempt Offering of Securities, item 06b
11/12/2014	Form 8-K	Current Report
10/14/2014	Form 10-K	Annual Report
09/24/2014	Form 8-K	Current Report
09/05/2014	Form 8-K	Current Report
09/05/2014	Form 8-K	Current Report
09/05/2014	Form 8-K	Current Report
09/05/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
09/05/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
09/05/2014	Form 3	Initial Statement of Beneficial Ownership of Securities
09/05/2014	Form 3	Initial Statement of Beneficial Ownership of Securities
07/30/2014	Form 10-Q	Quarterly Report
07/23/2014	Form 8-K	Current Report
07/21/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/21/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/21/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
07/01/2014	Form 8-K	Current Report
06/16/2014	Form 8-K/A	Amendment to Form 8-K
06/12/2014	DEF 14C	Definitive Information Statements
04/18/2014	Form 8-K	Current Report
04/16/2014	Form 3	Initial statement of beneficial ownership of securities
04/16/2014	Form 4	Statement of changes in beneficial ownership of securities
04/16/2014	Form 4	Statement of changes in beneficial ownership of securities
04/16/2014	Form 4	Statement of changes in beneficial ownership of securities
04/16/2014	Form 4	Statement of changes in beneficial ownership of securities
04/02/2014	Form D	Notice of Exempt Offering of Securities, item 06b
03/25/2014	Form 8-K	Current Report
03/24/2014	Form 8-K	Current Report
03/20/2014	Form 4	Statement of changes in beneficial ownership of securities
10/04/2013	Form 8-K	Current Report
06/19/2013	SC 13D	General statement of acquisition of beneficial ownership
06/19/2013	SC 13D-A	General statement of acquisition of beneficial ownership
06/19/2013	SC 13G	Statement of acquisition of beneficial ownership by individuals
05/09/2013	Form 3	Initial statement of beneficial ownership of securities
05/03/2013	Form 8-K	Current Report
04/05/2013	Form 8-K	Current Report
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
04/01/2013	Form 3	Initial statement of beneficial ownership of securities
03/28/2013	Form 8-K	Current Report
03/22/2013	SC 13D	General statement of acquisition of beneficial ownership
01/23/2013	Form 4	Statement of changes in beneficial ownership of securities
01/22/2013	SC 13D-A	General statement of acquisition of beneficial ownership
11/01/2012	Form 8-K	Current Report
10/04/2012	Form 8-K	Current Report
10/01/2012	Form 8-K	Current Report
09/19/2012	Form 3	Initial statement of beneficial ownership of securities
09/19/2012	Form 4	Statement of Changes in Beneficial Ownership of Securities
09/19/2012	SC 13G	Statement of acquisition of beneficial ownership by individuals
08/22/2012	Form D	Notice of Exempt Offering of Securities, item 06b
08/20/2012	Form 3	Initial statement of beneficial ownership of securities
08/20/2012	Form 3	Initial statement of beneficial ownership of securities
08/20/2012	Form 3	Initial statement of beneficial ownership of securities
08/20/2012	Form 4	Statement of changes in beneficial ownership of securities
08/20/2012	Form 4	Statement of changes in beneficial ownership of securities
08/20/2012	SC 13G	Statement of acquisition of beneficial ownership by individuals
08/16/2012	From 8-K	Current Report
08/16/2012	Form 10-Q	Quarterly Report
08/15/2012	From 8-K	Current Report
08/14/2012	Form 3	Initial statement of beneficial ownership of securities
08/14/2012	Form 4	Statement of changes in beneficial ownership of securities
08/14/2012	Form 4	Statement of changes in beneficial ownership of securities
08/14/2012	Form NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
08/09/2012	Form 3	Initial statement of beneficial ownership of securities
08/09/2012	From 8-K	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
08/07/2012	Form 4	Statement of changes in beneficial ownership of securities
07/27/2012	Form RW	Registration Withdrawal Request
07/23/2012	From 8-K	Current Report
06/27/2012	Form 4	Statement of changes in beneficial ownership of securities
06/27/2012	From 8-K	Current Report
06/27/2012	SC 13D-A	General statement of acquisition of beneficial ownership
06/21/2012	From 8-K	Current Report
06/18/2012	Form 4	Statement of changes in beneficial ownership of securities
06/14/2012	Form 4	Statement of changes in beneficial ownership of securities
06/12/2012	Form 4	Statement of changes in beneficial ownership of securities
06/07/2012	Form 4	Statement of changes in beneficial ownership of securities
06/07/2012	SC 13D-A	General statement of acquisition of beneficial ownership
06/04/2012	Form 4	Statement of changes in beneficial ownership of securities
06/01/2012	Form 4	Statement of changes in beneficial ownership of securities
05/30/2012	Form 4	Statement of changes in beneficial ownership of securities
05/25/2012	Form 4	Statement of changes in beneficial ownership of securities
05/23/2012	Form 4	Statement of changes in beneficial ownership of securities
05/21/2012	Form 4	Statement of changes in beneficial ownership of securities
05/21/2012	From 8-K	Current Report
05/16/2012	Form 4	Statement of changes in beneficial ownership of securities
05/15/2012	From 8-K	Current Report
05/15/2012	Form 10-Q	Quarterly Report
05/14/2012	Form 144-A	Report of proposed sale of securities
03/30/2012	From 8-K	Current Report
03/30/2012	Form 10-K	Annual Report

Recent Financial News for RSPI Headline RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties GlobeNewswire (Nov 20, 2025) RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement GlobeNewswire (Nov 19, 2025) RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock GlobeNewswire (Nov 18, 2025) RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement GlobeNewswire (Nov 18, 2025) RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties GlobeNewswire (Feb 10, 2025) RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury GlobeNewswire (May 29, 2024) RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury GlobeNewswire (Mar 20, 2024) RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine GlobeNewswire (Feb 13, 2024) RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors GlobeNewswire (Jan 22, 2024) RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient GlobeNewswire (Jan 04, 2024) RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development GlobeNewswire (Dec 11, 2023) RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services GlobeNewswire (Oct 12, 2023) RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company GlobeNewswire (Aug 09, 2023) ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs GlobeNewswire (May 24, 2023) RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders GlobeNewswire (Apr 05, 2023) RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation. GlobeNewswire (Apr 03, 2023) RespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of Directors GlobeNewswire (Mar 28, 2023) ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd GlobeNewswire (Mar 01, 2023) ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits GlobeNewswire (Feb 01, 2023) RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois GlobeNewswire (Jan 23, 2023) RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform GlobeNewswire (Jan 12, 2023) RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development GlobeNewswire (Dec 05, 2022) RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea GlobeNewswire (Nov 17, 2022) RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4 GlobeNewswire (Nov 10, 2022) RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit GlobeNewswire (Nov 07, 2022) RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition GlobeNewswire (Aug 08, 2022) RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit GlobeNewswire (May 24, 2022) RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics. GlobeNewswire (May 17, 2022) RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus GlobeNewswire (May 16, 2022) RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol GlobeNewswire (Mar 23, 2022) RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality GlobeNewswire (Mar 16, 2022) Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward GlobeNewswire (Mar 07, 2022) RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain GlobeNewswire (Jan 24, 2022) RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™ GlobeNewswire (Dec 14, 2021) RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81 GlobeNewswire (Dec 06, 2021) RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81 GlobeNewswire (Nov 30, 2021) RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury GlobeNewswire (Nov 29, 2021) RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast GlobeNewswire (Nov 22, 2021) RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO GlobeNewswire (Nov 04, 2021) RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference GlobeNewswire (Jun 08, 2021) RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury GlobeNewswire (May 12, 2021) RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs GlobeNewswire (Apr 22, 2021) Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI GlobeNewswire (Feb 08, 2021) RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split GlobeNewswire (Feb 08, 2021) RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences GlobeNewswire (Jan 08, 2021) RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split GlobeNewswire (Jan 05, 2020) RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows GlobeNewswire (Oct 27, 2020) RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury GlobeNewswire (Oct 06, 2020) RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development GlobeNewswire (Sep 25, 2020) RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property GlobeNewswire (Aug 04, 2020) RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer GlobeNewswire (Aug 03, 2020) RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer GlobeNewswire (May 06, 2020) RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc. GlobeNewswire (Mar 04, 2020) RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report GlobeNewswire (Feb 12, 2020) RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications GlobeNewswire (Feb 05, 2020) RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors GlobeNewswire (Feb 03, 2020) RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit GlobeNewswire (Sep 09, 2019) RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD. GlobeNewswire (Jul 30, 2019) RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia GlobeNewswire (Feb 19, 2019) RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors GlobeNewswire (Jan 03, 2019) RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit GlobeNewswire (Dec 10, 2018) RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc. GlobeNewswire (Sep 10, 2018) RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data: GlobeNewswire (Jul 25, 2018) RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso GlobeNewswire (Jun 19, 2018) Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc. GlobeNewswire (Jun 19, 2018) RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018 GlobeNewswire (Jan 08, 2018) RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development GlobeNewswire (Dec 18, 2017) RespireRx Pharmaceuticals Inc. Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt GlobeNewswire (Dec 15, 2017) RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea GlobeNewswire (Nov 30, 2017) RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference Marketwired (Sep 08, 2017) RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update Marketwired (Aug 25, 2017) RespireRx Pharmaceuticals Inc. to Present at the 2017 Marcum MicroCap Conference Marketwired (Jun 14, 2017) RespireRx Pharmaceuticals Inc. Announces Participation SLEEP 2017 in Boston, MA Marketwired (Jun 06, 2017) RespireRx Pharmaceuticals Inc. to Present at BIO CEO & Investor Conference 2017 Marketwired (Feb 10, 2017) RespireRx Pharmaceuticals Inc. to Present at 9th Annual Biotech Showcase(TM) 2017 Marketwired (Jan 06, 2017) RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea Marketwired (Dec 23, 2016) RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression Marketwired (Dec 15, 2016) RespireRx Pharmaceuticals Inc. Files September 30, 2016 Quarterly Report on Form 10-Q Marketwired (Nov 15, 2016) RespireRx Pharmaceuticals Inc. to Present at the BIO Investor Forum on Tuesday, October 18, 2016 at the St. Francis Hotel in San Francisco, California Marketwired (Oct 17, 2016) RespireRx Pharmaceuticals Inc. Retracts Efficacy Data in September 12, 2016 Press Release Announcing Preliminary Top-Line Analysis of Safety and Efficacy Data From Duke University Phase 2A Clinicial Trial of CX 1739 Marketwired (Oct 04, 2016) UPDATE - RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data From Duke University Phase 2A Clinical Trial of CX1739 Marketwired (Sep 12, 2016) RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data From Duke University Phase 2A Clinical Trial of CX1739 Marketwired (Sep 12, 2016) RespireRx Pharmaceuticals Inc. to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 12, 2016 Marketwired (Sep 08, 2016) RespireRx Pharmaceuticals Inc. Announces 1-for-325 Reverse Stock Split Marketwired (Sep 01, 2016) RespireRx Pharmaceuticals Inc. Files June 30, 2016 Quarterly Report on Form 10-Q Marketwired (Aug 15, 2016) RespireRx Pharmaceuticals Inc. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016 Marketwired (Jul 12, 2016) RespireRx Pharmaceuticals Inc. to Present at the Jefferies 2016 Healthcare Conference Marketwired (Jun 08, 2016) RespireRx Pharmaceuticals Inc. Files March 31, 2016 Quarterly Report on Form 10-Q Marketwired (May 16, 2016) RespireRx Pharmaceuticals Inc., the University of Alberta and the University of Florida Provide Update on Collaborative Research Activities Marketwired (Apr 01, 2016) RespireRx Pharmaceuticals Inc. Files December 31, 2015 Annual Report on Form 10-K Marketwired (Mar 29, 2016) RespireRx Pharmaceuticals Inc. to Present at the 28th Annual Roth Conference on March 15, 2016 Marketwired (Mar 11, 2016) RespireRx Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase 2A Clinical Trial by March 31, 2016 Marketwired (Feb 29, 2016) RespireRx Pharmaceuticals Inc. to Present at 18th Annual BIO CEO & Investor Conference Marketwired (Feb 04, 2016) RespireRx Pharmaceuticals Inc. to Present at Noble Financial Capital Markets' Twelfth Annual Investor/Equity Conference - NobleCon12 Marketwired (Jan 19, 2016) RespireRx Pharmaceuticals Inc. Announces New Research Program With the National Institute of Drug Abuse Marketwired (Jan 19, 2016) RespireRx Pharmaceuticals Inc. to Present at 8th Annual Biotech Showcase(TM) 2016 Marketwired (Jan 11, 2016) Cortex Pharmaceuticals, Inc. Announces Name Change and Symbol Change Marketwired (Dec 17, 2015) Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO Investor Forum Marketwired (October 19, 2015) Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 17th Annual Global Investment Conference Marketwired (September 8, 2015) Cortex Pharmaceuticals, Inc. Announces Initial Closing of Private Placement Marketwired (August 31, 2015) Cortex Pharmaceuticals, Inc. Announces Appointment of James S. J. Manuso, Ph.D., as President and Chief Executive Officer, Vice Chairman of the Board of Directors Marketwired (August 19, 2015) Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression Marketwired (June 30, 2015) Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders GlobeNewswire (May 04, 2015) Cortex Pharmaceuticals, Inc. to Present at NewYorkBIO 25th Anniversary Conference GlobeNewswire (May 01, 2015) Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form 10-K; Provides Update on Current Status and Activities GlobeNewswire (Apr 06, 2015)